2022 ASCO中国之声｜临床科学论坛、口头报告、壁报讨论部分共34项中国研究入选

临床科学论坛

01

摘要号： LBA4011

标题：Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: A prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial.

报告人：秦叔逵

单位：南京金陵医院

02

摘要号：106

标题：A study of AK104 (an anti-PD1 and anti-CTLA4 bispecific antibody) combined with standard therapy for the first-line treatment of persistent, recurrent, or metastatic cervical cancer (R/M CC).

报告人：王静

单位：湖南省肿瘤医院

03

摘要号：7008

标题：Autologous CD19-directed CAR T cells produced by novel PrimeCAR manufacture platform exhibit safety, efficacy, and long persistence profiles in relapsed/refractory B-lineage acute leukemia (r/r B-ALL).

报告人：黎诗琦

单位：中国人民解放军联勤保障部队第九二〇医院

口头报告

01

摘要号：3000

标题：A phase Ia/Ib study of CBP-1008, a bispecific ligand drug conjugate, in patients with advanced solid tumors.

报告人：吴令英

单位：中国医学科学院肿瘤医院

02

摘要号：3500

标题：Perioperative chemotherapy with mFOLFOX6 or CAPOX for patients with locally advanced colon cancer (OPTICAL): A multicenter, randomized, phase 3 trial.

报告人：胡华斌

单位：中山大学附属第六医院

03

摘要号：4507

标题：TRUCE-02: An open label, single-arm, phase II study of tislelizumab combined with nab-paclitaxel for high-risk non-muscle-invasive urothelial bladder carcinoma.

报告人：王海涛

单位：天津医科大学第二医院

04

摘要号：5005

标题：A phase 3 trial of SHR3680 versus bicalutamide in combination with androgen deprivation therapy (ADT) in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC).

报告人：叶定伟

单位：复旦大学附属肿瘤医院

05

摘要号：6000

标题：Radiotherapy alone versus concurrent chemoradiotherapy in intermediate risk nasopharyngeal carcinoma: A multicentre, open-label, noninferiority, randomised phase III trial.

报告人：马骏

单位：中山大学肿瘤防治中心

06

摘要号：6001

标题：Nimotuzumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC): A prospective, randomized-controlled, double-blinded, multicenter phase III clinical trial.

报告人：孙艳

单位：北京大学肿瘤医院

07

摘要号：6002

标题：Reduced-dose radiotherapy for pretreatment EBV DNA selected low-risk stage III nasopharyngeal carcinoma: A single-arm, phase II trial.

报告人：麦海强

单位：中山大学肿瘤防治中心

08

摘要号：7501

标题：GEMSTONE-201: Preplanned primary analysis of a multicenter, single-arm, phase 2 study of sugemalimab (suge) in patients (pts) with relapsed or refractory extranodal natural killer/T cell lymphoma (R/R ENKTL).

报告人：黄慧强

单位：中山大学肿瘤防治中心

09

摘要号：8004

标题：Phase I open-label single arm study of GPRC5D CAR T-cells (OriCAR-017) in patients with relapsed/refractory multiple myeloma (POLARIS).

报告人：黄河

单位：浙江大学医学院附属第一医院

10

摘要号：8005

标题：Updated results of a multicenter first-in-human study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM).

报告人：杜鹃

单位：上海长征医院

11

摘要号：8500

标题：Two cycles versus three cycles of neoadjuvant sintilimab plus platinum-doublet chemotherapy in patients with resectable non-small-cell lung cancer (neoSCORE): A randomized, single center, two-arm phase II trial.

报告人：邱福铭

单位：浙江大学医学院附属第二医院

12

摘要号：8505

标题：Serplulimab, a novel anti-PD-1 antibody, plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small-cell lung cancer: An international randomized phase 3 study.

报告人：程颖

单位：吉林省肿瘤医院

13

摘要号：9508

标题：A phase II clinical trial of camrelizumab (CAM, an IgG4 antibody against PD-1) combined with apatinib (APA, a VEGFR-2 tyrosine kinase inhibitor) and temozolomide (TMZ) as the first-line treatment for patients (pts) with advanced acral melanoma (AM).

报告人：斯璐

单位：北京大学肿瘤医院

14

摘要号：11502

标题：Phase I clinical trial to assess safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of NY-ESO-1–specific TCR T-cells (TAEST16001) in HLA-A*02:01 patients with advanced soft tissue sarcoma.

报告人：张星

单位：中山大学肿瘤防治中心

15

摘要号：12001

标题：Correlation of psychological distress with quality of life and efficacy of immune checkpoint inhibitors in patients with newly diagnosed stage IIIB-IV NSCLC.

报告人：吴芳

单位：中南大学湘雅二医院

壁报讨论

01

摘要号：2512

标题：Phase I/IIa study of PM8001, a bifunctional fusion protein targeting PD-L1 and TGF‑β, in patients with advanced tumors.

报告人：郭晔

单位：同济大学附属东方医院

02

摘要号：3011

标题：A multicenter, open-label, single-arm, phase 1 dose-escalation study to evaluate the safety, tolerability, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1.

报告人：胡晓洁

单位：上海交通大学医学院附属第九人民医院

03

摘要号：3515

标题：Primary surgery followed by selective radiochemotherapy versus conventional preoperative radiochemotherapy for patients with locally advanced rectal cancer with MRI-negative circumferential margin (PSSR): A multicenter, randomized, open-label, noninferiority, phase 3 trial.

报告人：丁克峰

单位：浙江大学医学院附属第二医院

04

摘要号：3516

标题：Short-term outcomes of laparoscopy-assisted versus open surgery for low rectal cancer (LASRE): A multicenter, randomized, controlled trial.

报告人：池畔

单位：福建医科大学附属协和医院

05

摘要号： 4013

标题：Postoperative adjuvant hepatic arterial infusion chemotherapy (HAIC) with FOLFOX to improve outcomes of patients with hepatocellular carcinoma with microvascular invasion: A prospective multicenter, phase 3, randomized, controlled clinical trial.

报告人：李少华

单位：中山大学肿瘤防治中心

06

摘要号：4016

标题：Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial (NXCEL1311 Study).

报告人：孟雪

单位：山东省肿瘤医院

07

摘要号：4017

标题：Safety, tolerability, and preliminary efficacy results in patients with advanced gastric/gastroesophageal junction adenocarcinoma from a phase Ib/II study of CLDN18.2 CAR T-cell therapy (CT041).

报告人：齐长松

单位：北京大学肿瘤医院

08

摘要号：4518

标题：Preliminary results of a phase Ib/II combination study of RC48-ADC, a novel humanized anti-HER2 antibody-drug conjugate (ADC) with toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) in patients with locally advanced or metastatic urothelial carcinoma.

报告人：盛锡楠

单位：北京大学肿瘤医院

09

摘要号：4519

标题：A phase II study of RC48-ADC in HER2-negative patients with locally advanced or metastatic urothelial carcinoma.

报告人：Huayan Xu

单位：北京大学肿瘤医院

10

摘要号：4520

标题：RC48-ADC for metastatic urothelial carcinoma with HER2-positive: Combined analysis of RC48-C005 and RC48-C009 trials.

报告人：盛锡楠

单位：北京大学肿瘤医院

11

摘要号：6012

标题：Efficacy and safety of camrelizumab and apatinib combined with induction chemotherapy and concurrent chemoradiotherapy for stage TanyN3M0 nasopharyngeal carcinoma: A phase II QUINTUPLED trial.

报告人：Hu Liang

单位：中山大学肿瘤防治中心

12

摘要号：7513

标题：Interim results of a phase II multicenter study with the oral histone deacetylase inhibitor abexinostat in patients with relapsed/refractory follicular lymphoma.

报告人：桂琳

单位：中国医学科学院肿瘤医院

13

摘要号：8516

标题：Sintilimab plus anlotinib as second or further-line therapy for small cell lung cancer: An objective performance trial.

报告人：马淑香

单位：河南省肿瘤医院

14

摘要号：9512

标题：Toripalimab plus axitinib versus toripalimab or axitinib alone in patients with treatment-naive unresectable or metastatic mucosal melanoma: Interim results from a randomized, controlled, phase II trial.

报告人：崔传亮

单位：北京大学肿瘤医院

15

摘要号：11513

标题：Promising antitumor activity of olverembatinib (HQP1351) in patients (pts) with tyrosine kinase inhibitor- (TKI-) resistant succinate dehydrogenase- (SDH-) deficient gastrointestinal stromal tumor (GIST).

报告人：邱海波

单位：中山大学肿瘤防治中心

16

摘要号：11519

标题：Phase I study of pegylated liposomal doxorubicin in combination with cyclophosphamide and vincristine in pediatric patients with relapsed/refractory sarcoma and other malignant solid tumors.

报告人：路素英

单位：中山大学肿瘤防治中心

备注：排名不分先后，按照摘要号进行